FDA Approves Tirzepatide (Zepbound) for Chronic Weight Management

Announced on November 8, 2023, the approval of tirzepatide(Zepbound) was awarded to Eli Lilly and Company and represents the first chronic weight management approval for a dual GLP-1/GIP receptor agonist.

Related Keywords

United States ,W Timothy Garvey ,Timothy Garvey ,Eli Lilly ,John Sharretts ,Joe Nadglowski ,Obesity Action Coalition ,Drug Administration ,Division Of Diabetes ,Office Of The Commissioner ,Lipid Disorders ,Drug Evaluation ,Priority Review ,Fast Track ,Obesity Action ,Chronic Weight Management ,